Table 1.
Baseline characteristics of 116 with RA-ILD treated with DMARDs.
| Variable | Total = 116 |
|---|---|
| Epidemiological characteristics | |
| Female sex, n (%) | 63 (54.3) |
| Caucasian race, n (%) | 113 (97.4) |
| Age, years, mean (SD) | 68.3 (9.9) |
| Clinical and analytical characteristics | |
| Current smoker | – |
| Nonsmoker, n (%) | 57 (49.1) |
| Smoker, n (%) | 23 (19.8) |
| Exsmoker, n (%) | 36 (31.0) |
| Body mass index, mean (SD) | 27.8 (4.1) |
| Time since diagnosis of RA, months, median (25%–75%) | 148.5 (71.5–217.8) |
| Diagnostic delay, months, median (25%–75%) | 8.5 (4.9–16.8) |
| Time since diagnosis of ILD, months, median (25%–75%) | 27.5 (9.8–60.0) |
| Positive rheumatoid factor (>10), n (%) | 111 (95.7) |
| Positive ACPA titer (>20), n (%) | 100 (86.2) |
| High ACPA titer (>340), n (%) | 48 (41.4) |
| Erosive disease, n (%) | 76 (65.5) |
| Sjögren syndrome, n (%) | 18 (15.5) |
| Osteoporosis, n (%) | 51 (44.0) |
| Treatment | |
| Synthetic DMARD | 100 (86.2) |
| Methotrexate, n (%) | 51 (44.0) |
| Leflunomide, n (%) | 30 (25.9) |
| Sulfasalazine, n (%) | 9 (7.8) |
| Hydroxychloroquine, n (%) | 21 (18.1) |
| Biologic DMARD | 50 (43.1) |
| Infliximab, n (%) | 1 (0.9) |
| Etanercept, n (%) | 6 (5.2) |
| Adalimumab, n (%) | 3 (2.6) |
| Golimumab, n (%) | 3 (2.6) |
| Certolizumab, n (%) | 3 (2.6) |
| Tocilizumab, n (%) | 6 (5.2) |
| Abatacept, n (%) | 15 (12.9) |
| Rituximab, n (%) | 13 (11.2) |
| Immunosuppressants | 11 (9.5) |
| Mycophenolate, n (%) | 7 (6.0) |
| Azathioprine, n (%) | 4 (3.4) |
| Antifibrotic agents, nintedanib, n (%) | 1 (0.9) |
| Baseline corticosteroids, n (%) | 69 (60.0) |
| Dose of baseline corticosteroids, median (25%–75%) | 5.0 (0.0–7.5) |
SD: standard deviation; RA: rheumatoid arthritis; ILD: interstitial lung disease; ACPA: anticyclic citrullinated protein antibody; DMARD: disease-modifying antirheumatic drug.